Tower Research Capital (TRC)’s AEON Biopharma AEON Stock Holding History

Tower Research Capital (TRC)’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$463	Buy	+470	New	+$525	﹤0.01%	4866
2025 Q1	–	Sell	-117	Closed	-$4.53K	–	5136
2024 Q4	$4.53K	Buy	117 +44	+60%	+$2.56K	﹤0.01%	4445
2024 Q3	$5.52K	Buy	73 +2	+3%	+$176	﹤0.01%	4258
2024 Q2	$5.36K	Buy	71 +58	+446%	+$13.8K	﹤0.01%	4692
2024 Q1	$11.2K	Buy	13 +12	+1,200%	+$8.69K	﹤0.01%	3592
2023 Q4	$713	Sell	1 -5	-83%	-$2.01K	﹤0.01%	5507
2023 Q3	$2.5K	Buy	+6	New	+$2.75K	﹤0.01%	5140
2022 Q1	–	Sell	-2	Closed	-$2K	–	6050
2021 Q4	$2K	Buy	+2	New	+$1.41K	﹤0.01%	5592

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s AEON Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in AEON Biopharma (AEON) in Q1 2026: 470 shares worth $463. The stake represents ﹤0.01% of the portfolio and ranks #4866 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in AEON as recently as Q4 2024.

Tower Research Capital (TRC) first reported a position in AEON in Q4 2021 and has held it in 8 quarters since. The position peaked at $11.2K in Q1 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

Tower Research Capital (TRC) held 470 shares of AEON Biopharma worth $463 as of Q1 2026.
AEON Biopharma was a new Tower Research Capital (TRC) position in Q1 2026.
AEON Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4866 holding.
Tower Research Capital (TRC) first reported a position in AEON Biopharma in Q4 2021 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s AEON Biopharma position peaked at $11.2K in Q1 2024.
24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.